KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amgen (AMGN) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Amgen (AMGN) over the last 17 years, with Q3 2025 value amounting to $28.0 million.

  • Amgen's Gains from Investment Securities rose 18000.0% to $28.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$88.0 million, marking a year-over-year decrease of 15677.42%. This contributed to the annual value of -$50.0 million for FY2024, which is 9111.9% up from last year.
  • Amgen's Gains from Investment Securities amounted to $28.0 million in Q3 2025, which was up 18000.0% from $23.0 million recorded in Q2 2025.
  • Amgen's 5-year Gains from Investment Securities high stood at $440.0 million for Q3 2021, and its period low was -$492.0 million during Q3 2023.
  • In the last 5 years, Amgen's Gains from Investment Securities had a median value of -$9.0 million in 2022 and averaged $2.8 million.
  • Per our database at Business Quant, Amgen's Gains from Investment Securities soared by 142142.86% in 2022 and then crashed by 536666.67% in 2023.
  • Over the past 5 years, Amgen's Gains from Investment Securities (Quarter) stood at $28.0 million in 2021, then surged by 1421.43% to $426.0 million in 2022, then plummeted by 96.24% to $16.0 million in 2023, then plummeted by 1281.25% to -$189.0 million in 2024, then skyrocketed by 114.81% to $28.0 million in 2025.
  • Its Gains from Investment Securities was $28.0 million in Q3 2025, compared to $23.0 million in Q2 2025 and $50.0 million in Q1 2025.